4:12 PM
 | 
Nov 06, 2018
 |  BC Extra  |  Preclinical News

Hopkins study props up PARP inhibitors for Parkinson's

A study in mice showed the potential of repurposed PARP-1 inhibitors to reverse aggregate α-synuclein-induced neuronal cell death in Parkinson's disease.

PARP inhibitors Lynparza olaparib, Zejula niraparib, Talzenna talazoparib and Rubraca rucaparib are marketed or approved for cancers where PARP-1 is necessary for DNA repair. Earlier studies had shown that PARP-1 activation also led to...

Read the full 254 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >